Navigation Links
PDL BioPharma Announces Third Quarter 2011 Financial Results
Date:11/9/2011

rent year earnings and cash on hand. As of September 30, 2011, the Company has accrued $21.0 million in dividends payable for the December 15, 2011, dividend.

Adjustments to Convertible Note Conversion RatiosIn connection with the September 15, 2011, dividend payment, the conversion ratios for PDL's convertible notes increased. The conversion ratio for the 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), was adjusted to 151.713 shares of common stock per $1,000 principal amount, or approximately $6.59 per share, effective September 9, 2011. The conversion ratio for the May 2015 Notes was adjusted to 132.6682 shares of common stock per $1,000 principal amount, or approximately $7.54 per share, effective September 6, 2011. The conversion ratio for the February 2015 Notes was previously 147.887 shares of common stock per $1,000 principal amount, or a conversion price of approximately $6.76 per share. The conversion ratio for the May 2015 Notes was previously 129.2740 shares of common stock per $1,000 principal amount, or a conversion price of approximately $7.74 per share.

Genentech and Roche DisputePDL received a letter from Genentech, Inc. (Genentech) in August 2010 sent on behalf of F. Hoffman-La Roche Ltd. (Roche) and Novartis AG (Novartis), asserting that Avastin, Herceptin, Lucentis and Xolair (the Genentech Products) do not infringe PDL's supplementary protection certificates (SPCs) granted to the Company by various countries in Europe for each of the Genentech Products and seeking a response to these assertions. The SPCs covering the Genentech Products effectively extend the patent protection for PDL's European Patent No. 0 451 216B (the '216B Patent) until December 2014, except that the SPCs for Herceptin will generally expire in July 2014. PDL responded to Genentech, stating that the Company believes its assertions of non-infringement are without merit and that it disagreed fundamentally with the assertion
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
2. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
3. PDL BioPharma to Announce Third Quarter 2011 Financial Results on November 9, 2011
4. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
5. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
6. Sentry BioPharma Services Earns a GSA Federal Supply Schedule Contract #GS-10F-0432X
7. Genesis Biopharma Signs Worldwide License Agreement with the NIH for Adoptive Cell Therapy to Treat a Variety of Cancers
8. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
9. CoLucid Pharmaceuticals to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan
10. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
11. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will increase to a value of over ... by expansion in the large direct energy device market. ... increasingly adopted due to the advantages they offer and ... findings from Decision Resources Group,s coverage of the U.S. ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana Therapeutics, ... biopharmaceutical company focused on the licensing, development and ... announced positive results from its pivotal field study ... treating pain in dogs with osteoarthritis.  In the ... assessment scores that were statistically significant compared to ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... Development for Chronic Pain and Non-Pain ... Indications -, ... ) today announced that data from its multiple dose clinical,trial of tezampanel, ... the product candidate is safe and,well-tolerated in normal male and female subjects., ...
... Show PTC124 Addresses Underlying Cause of Genetic Disorders and ... Protein Function in Cystic Fibrosis Model, SOUTH PLAINFIELD, N.J., ... new preclinical data in the February 12,2008 edition of the ... PTC124, a novel drug designed to bypass nonsense mutations,was active ...
Cached Medicine Technology:Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 2Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 3Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 4PTC Therapeutics Announces Publication of Preclinical Data in PNAS 2PTC Therapeutics Announces Publication of Preclinical Data in PNAS 3PTC Therapeutics Announces Publication of Preclinical Data in PNAS 4
(Date:12/22/2014)... Carlsbad, Ca (PRWEB) December 22, 2014 ... providing superior senior care service in San ... providing all members of its senior care team ... for caregivers from Golden Care is provided by ... seniors and professional caregivers with the most reliable ...
(Date:12/22/2014)... 22, 2014 Sagacious Consultants, the premier ... subscription option to their ad hoc report writing service ... Customers can sign up for an annual subscription and ... month at a deeply discounted hourly rate. , ... has a progressively discounted rate. Subscription hours are contracted ...
(Date:12/22/2014)... NC (PRWEB) December 22, 2014 ... the current Ebola virus epidemic are receiving ... U.S. government agencies, nongovernmental organizations (NGOs) and ... remains ongoing, healthcare workers, emergency responders, patients ... technologies such as the CmTP MediDefense ...
(Date:12/22/2014)... York, NY (PRWEB) December 22, 2014 ... 2014 stronger than ever, having invested more than ... injured service members, veterans and their families. , ... for nearly a dozen nonprofits, helping with: veteran ... nursing scholarships; and life-coaches for severely injured veterans. ...
(Date:12/22/2014)... 22, 2014 Give a loved one ... gift of health and vitality. , For a limited ... top-selling anti-aging formulas in special Holiday Wellness gift packages ... , Each bottle contains cutting-edge, proven nutritional support ... work as well as we age. , ...
Breaking Medicine News(10 mins):Health News:Golden Care Partners with Nationally Recognized Caregiver Training Service 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2
... , , SOLON, Ohio, Aug. ... U.S. marketplace, Nestle USA is pleased to announce that NESTLE TOLL ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090818/SF63053-a ) , (Photo: http://www.newscom.com/cgi-bin/prnh/20090818/SF63053-b ) ... retail partners and consumers to identify the new batch of cookie ...
... home foreclosure epidemic may be taking its toll on ... of people studied while undergoing foreclosure reported depressive symptoms, ... according to new University of Pennsylvania School of Medicine ... Journal of Public Health. Many also reported an ...
... in the normal range appear to be associated with ... new study published online August 21 in the ... growth factors appear to be involved in the development ... levels and prostate cancer risk has been unclear. ...
... ... control a cell,s ability to adapt to changes in its environment, a finding that could ... , ... August 21, 2009 -- UCSF researchers have identified the two key circuits that control a ...
... , DALLAS, Aug. 21 Michael Ramsay, ... chief of the department of anesthesiology and pain management ... elected president of the International Liver Transplant Society (ILTS), ... international members specializing in hepatology, surgery, anesthesia, critical care, ...
... , , , , ... America, Inc., a leader in the home and office bottled water, filtration ... a three-year alliance with Susan G. Komen for the Cure(R), the world,s ... office bottled water brands, DS Waters will make a $30.00 donation to ...
Cached Medicine News:Health News:Updated With Photos: NESTLE(R) TOLL HOUSE(R) Re-launches With 'New Batch' Label 2Health News:More than 1/3 of homeowners in foreclosure suffer from major depression, Penn study shows 2Health News:More than 1/3 of homeowners in foreclosure suffer from major depression, Penn study shows 3Health News:UCSF Researchers Identify Two Key Pathways in Adaptive Response 2Health News:UCSF Researchers Identify Two Key Pathways in Adaptive Response 3Health News:UCSF Researchers Identify Two Key Pathways in Adaptive Response 4Health News:Dallas Physician Elected to Lead International Organ Transplant Society 2Health News:Dallas Physician Elected to Lead International Organ Transplant Society 3Health News:DS Waters of America, Inc. Partners With Susan G. Komen for the Cure(R) 2Health News:DS Waters of America, Inc. Partners With Susan G. Komen for the Cure(R) 3Health News:DS Waters of America, Inc. Partners With Susan G. Komen for the Cure(R) 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: